Cambridge, United Kingdom · Founded 2019 · Privately Held (backing)
Developer of allosteric small molecule inhibitors targeting MSH3/MutSbeta designed to treat Huntington's disease and other triplet repeat neurodegenerative disorders. LoQus23 Therapeutics is based in Cambridge, United Kingdom and was founded in 2019. Its last known valuation is $61.4 million. It has raised $67.2 million.
These 3 firms already write checks for companies like LoQus23 Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.